Aardvark Therapeutics, Inc. Common Stock (AARD)
Aardvark Therapeutics, Inc. Common Stock operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $6.93, down 3.62% on the session, giving a market capitalisation of $151.7M. On trailing twelve-month figures it carries a trailing P/E of -2.16, a net margin of 0.0%. Its beta of 3.81 implies it has historically moved more than the broad market.
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
Aardvark Therapeutics, Inc. Common Stock is most often compared with the following Healthcare names: